Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Revenue projections:

Amgen Inc.'s projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio	1.371000
forwardPE	17.654253
debtToEquity	490.281000
earningsGrowth	0.649000
revenueGrowth	0.095000
grossMargins	0.718910
operatingMargins	0.355480
trailingEps	16.100000
forwardEps	24.497780

Amgen Inc.'s current ratio, being 1.371, means the company is well-positioned to meet its short-term debt obligations. This reflects Amgen Inc.'s strong liquidity, as its cash reserves and current assets provide more than enough coverage for its immediate liabilities.
AMGN's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
Amgen Inc.'s elevated debt-to-equity ratio suggests the company is highly leveraged, meaning it has significant debt compared to equity. This can be risky, particularly if Amgen Inc.'s cash flow or profits decrease, making it harder to meet debt obligations.
AMGN's positive gross and operating margins reflect strong financial performance. These metrics indicate that the company is efficiently managing its operations and generating healthy profits, contributing to a solid financial position.
AMGN's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that AMGN is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Over time, price projections for AMGN have risen steadily, pointing to growing optimism among analysts about the company's future. This upward trend suggests a positive outlook for AMGN's continued growth.

Insider Transactions:

AMGN had 8 sell transactions, while the market price was at 358.7712516784668 per share.There were no sell transactions recorded during the period under consideration.More buys than sells have been occurring around the current price levels of Amgen Inc., potentially signaling investor optimism. This buying trend might be interpreted as a sign of a favorable outlook for the stock's future performance.

Recommendation changes over time:

With analysts showing a buy bias for Amgen Inc., investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning Amgen Inc. as a safe and profitable place for investors to allocate their funds and seek growth.